Aclaris Therapeutics (ACRS) Cash from Restructuring (2016)

Aclaris Therapeutics (ACRS) posted quarterly Cash from Restructuring of $2.8 million for Q1 2016.

Aclaris Therapeutics (ACRS) Cash from Restructuring (2016) Analysis & Trends

Aclaris Therapeutics' Cash from Restructuring history runs 1 years deep, the most recent figure standing at $2.8 million for Q1 2016.

In Q1 2016, Cash from Restructuring changed N/A year-over-year to $2.8 million; the TTM figure through Dec 2016 stood at $2.8 million (changed N/A YoY), while the FY2016 annual figure was $2.8 million, changed N/A from the prior year.
Cash from Restructuring for Q1 2016 stood at $2.8 million.
The five-year high for Cash from Restructuring was $2.8 million in Q1 2016, with the low at $2.8 million in Q1 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Aclaris Therapeutics	808.18 Mn	716.63 Mn	1.41 Mn

Historic Data

Download Data

Date	Value
Mar 31, 2016	2.78 Mn